公司資料
Seagen 股價、新聞與催化劑
- 股票代碼:
- SGEN
- 交易所:
- NASDAQ
- 產業:
- Antibody Drugs, ADCs
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for SGEN.
公司概覽
業務概覽
Seagen was a biotechnology company focused on antibody-drug conjugates and oncology before being acquired by Pfizer. Its identity was tied to cancer therapeutics and the broader validation of ADC technology.
所在地與產業分類
Seagen was headquartered in the United States and listed on NASDAQ before its acquisition. It sat in oncology biotechnology with a strong U.S. commercial and development presence.
商業模式特徵
The business depended on oncology product sales, ADC innovation, and the ability to expand the reach of its platform through development and partnership activity. Investors focused on clinical data, label expansion, and the strategic value of its ADC franchise.
生技產業定位
Seagen was one of the most important ADC-focused biotech companies of its time. It occupied a high-catalyst position because oncology readouts and platform validation directly influenced the stock.
未來催化劑
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。